Plasticity within striatal direct pathway neurons after neonatal dopamine depletion is mediated through a novel functional coupling of serotonin 5-HT2 receptors to the ERK 1/2 map kinase pathway

被引:25
作者
Brown, Pierre [1 ]
Gerfen, Charles R. [1 ]
机构
[1] NIMH, Lab Syst Neurosci, NIH, Bethesda, MD 20892 USA
关键词
striatum; receptor coupling; serotonin;
D O I
10.1002/cne.21034
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Dysfunction within the striatal direct and indirect projecting systems arises after 6-hydroxydopamine (6-OHDA)-induced dopamine depletion, highlighting the central regulatory function of dopamine in motor systems. However, the striatal 5-hydroxytryptamine (5-HT) innervation remains intact after 6-OHDA lesions, suggesting that the 5-HT system may contribute to the lesion-induced dysfunction, or alternatively, it may adapt and compensate for the dopamine deficit. Neonatal 6-OHDA lesions actually give rise to a 5-HT axonal hyperinnervation within the dorsal striatum, further reinforcing the idea that the 5-HT system plays a central role in striatal function after dopamine depletion. Here we show that neonatal but not adult 6-OHDA lesions result in a novel coupling of 5-HT, receptors to the ERK1/2/MAP Kinase pathway, a signaling cascade known to regulate neuronal plasticity. Chloroamphetamine-induced 5-HT release or direct stimulation of striatal 5-HT, receptors via the 5-HT, agonist DOI, produced robust ERK1/2 phosphorylation throughout the dorsal striatum of neonatal lesioned animals, a response not observed within the intact striatum. Pretreatment with the select 5-HT, receptor antagonist Ketanserin blocked DOI-induced ERK1/2 phosphorylation. This drug-induced ERK1/2 phosphorylation was subsequently shown to be restricted to direct pathway striatal neurons. Our data show that adaptation of direct pathway neurons after neonatal 6-OHDA lesions involves coupling of 5-HT, receptors to the ERK1/2/MAP Mnase cascade, a pathway not typically active in these neurons. Because dopamine-mediated signaling is redundant after 6-OHDA lesions, 5-HT-mediated stimulation of the ERK1/2/MAP Mnase pathway may provide an alternative signaling route allowing the regulation of neuronal gene expression and neuronal plasticity in the absence of dopamine.
引用
收藏
页码:415 / 430
页数:16
相关论文
共 70 条
[1]   UNILATERAL DOPAMINE LESIONS IN NEONATAL, WEANLING AND ADULT-RATS - COMPARISON OF ROTATION AND REACHING DEFICITS [J].
ABROUS, DN ;
WAREHAM, AT ;
TORRES, EM ;
DUNNETT, SB .
BEHAVIOURAL BRAIN RESEARCH, 1992, 51 (01) :67-75
[2]   A review of central 5-HT receptors and their function [J].
Barnes, NM ;
Sharp, T .
NEUROPHARMACOLOGY, 1999, 38 (08) :1083-1152
[3]   Serotonin 2A receptor mRNA levels in the neonatal dopamine-depleted rat striatum remain upregulated following suppression of serotonin hyperinnervation [J].
Basura, GJ ;
Walker, PD .
DEVELOPMENTAL BRAIN RESEARCH, 1999, 116 (01) :111-117
[4]   Stimulated serotonin release from hyperinnervated terminals subsequent to neonatal dopamine depletion regulates striatal tachykinin, but not enkephalin gene expression [J].
Basura, GJ ;
Walker, PD .
MOLECULAR BRAIN RESEARCH, 2000, 81 (1-2) :80-91
[5]   Serotonin 2A receptor regulation of striatal neuropeptide gene expression is selective for tachykinin, but not enkephalin neurons following dopamine depletion [J].
Basura, GJ ;
Walker, PD .
MOLECULAR BRAIN RESEARCH, 2001, 92 (1-2) :66-77
[6]  
BHAT RV, 1992, J PSYCHIATR NEUROSCI, V17, P94
[7]   Serotonin 5-HT2A receptors underlie increased motor behaviors induced in dopamine-depleted rats by intrastriatal 5-HT2A/2C agonism [J].
Bishop, C ;
Tessmer, JL ;
Ullrich, T ;
Rice, KC ;
Walker, PD .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2004, 310 (02) :687-694
[8]   Intrastriatal serotonin 5-HT2 receptors mediate dopamine D1-induced hyperlocomotion in 6-hydroxydopamine-lesioned rats [J].
Bishop, C ;
Kamdar, DP ;
Walker, PD .
SYNAPSE, 2003, 50 (02) :164-170
[9]   6-HYDROXYDOPAMINE INDUCES SEROTONERGIC AXON SPROUTING IN CEREBRAL-CORTEX OF NEWBORN RAT [J].
BLUE, ME ;
MOLLIVER, ME .
DEVELOPMENTAL BRAIN RESEARCH, 1987, 32 (02) :255-269
[10]  
BREESE GR, 1984, J PHARMACOL EXP THER, V231, P343